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Aims To critically review the available transcatheter aortic valve implantation techniques and their results, as well as
propose recommendations for their use and development.
Methods and
results
A committee of experts including European Association of Cardio-Thoracic Surgery and European Society of Car-
diology representatives met to reach a consensus based on the analysis of the available data obtained with transcath-
eter aortic valve implantation and their own experience. The evidence suggests that this technique is feasible and
provides haemodynamic and clinical improvement for up to 2 years in patients with severe symptomatic aortic ste-
nosis at high risk or with contraindications for surgery. Questions remain mainly concerning safety and long-term
durability, which have to be assessed. Surgeons and cardiologists working as a team should select candidates,
perform the procedure, and assess the results. Today, the use of this technique should be restricted to high-risk
patients or those with contraindications for surgery. However, this may be extended to lower risk patients if the
initial promise holds to be true after careful evaluation.
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Conclusion Transcatheter aortic valve implantation is a promising technique, which may offer an alternative to conventional
surgery for high-risk patients with aortic stenosis. Today, careful evaluation is needed to avoid the risk of uncontrolled
diffusion.
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Preamble
Valve disease is an important public health problem, as it carries a
poor prognosis and its prevalence is strongly linked to the phenom-
enon of population ageing.1 The most frequent native valve disease in
Europe is currently aortic stenosis (AS), which is most often seen in
elderly patients with comorbidities.2 Valve replacement is the defini-
tive therapy for patients with severe AS who have symptoms or
objective consequences such as left ventricular (LV) dysfunction.3,4
Operative mortality is quite low, even in elderly patients when prop-
erly selected, and long-term results have been shown to be satisfac-
tory.5,6 However, the risk of surgery may be higher in elderly patients
with significant comorbidities. In addition, several registries show
that referring physicians often do not propose surgery, as was the
case in the Euro Heart Survey with 33% of patients with severe
valve disease and severe symptoms not being considered for
surgery.7 Thus, despite the good results of valve surgery, there
may well be a role for less invasive alternatives.
Balloon aortic valvuloplasty (BAV) is now rarely used, mainly
due to its limited long-term efficacy.2
Six years after the first in man,8 transcatheter aortic valve
implantation (TAVI) for the treatment of AS currently represents
a dynamic field of research and development: two devices have
been CE-marked and are being commercialized.
At this point in time, it is important for professional societies to
critically review the available TAVI techniques and their results, as
well as propose recommendations for their use, development in
clinical practice, and further research.9,10 On the 18–19th of
November 2007, a committee of experts, including EACTS and
ESC representatives, met. The consensus reached is summarized
in the current document, which was approved first by the commit-
tee members and subsequently by the board of both professional
societies involved.
The Committee acknowledges that the conclusions in this docu-
ment rely on limited data reported mostly in oral communications
and few in peer-reviewed journals and are temporally limited by
the very nature of the document.
Current techniques and results
Two devices are under clinical investigation for TAVI. One device is
the Edwards-Sapien valve (Edwards Lifesciences Inc., CA, USA),
which consists of three pericardial leaflets, initially equine and cur-
rently bovine, mounted within a tubular, slotted, stainless steel,
balloon-expandable stent. It is currently available in 23 and
26 mm sizes, necessitating, for the transfemoral approach, respect-
ively, 22 and 24F introducer sheaths, and for the transapical
approach, this measurement was 33F and is now 26F. The other
device is the CoreValve Revalving System (CRS TM, CoreValve
Inc., Irvine, CA, USA), which has three pericardial leaflets, initially
bovine and currently porcine, mounted in a self-expanding,
nitinol frame. It is available in 26 and 29 mm sizes, which go
through an 18F introducer for transfemoral use, or very recently
21F for the transapical route. (NB: the measurements of prosthesis
size quoted by the manufacturers do not correspond exactly to
those of surgically implanted prostheses).
Techniques of implantation
TAVI is currently carried out using two different approaches (ret-
rograde transfemoral and anterograde transapical), which share
the same main principles.
† Most teams perform the procedure under general anaesthesia,
although sedation and analgesia may suffice for the transfemoral
approach.
† Peri-procedural transoesophageal echocardiography (TEE)
monitoring is desirable to correctly position the valve as well
as to detect complications.
† After crossing the aortic valve, BAV is performed to pre-dilate
the native valve and serve as a rehearsal for TAVI. Simultaneous
rapid pacing decreases cardiac output, stabilizing the balloon
during inflation. Normal blood pressure must be completely
recovered between sequences of rapid pacing.
† The following imaging methods can be used to position the
prosthesis at the aortic valve:
W Fluoroscopy to assess the level of valve calcification.
W Aortography, using different views, performed at the begin-
ning of the procedure and eventually repeated with the unde-
ployed prosthesis in place, to determine the position of the
valve and the plane of alignment of the aortic cusps.
W Echocardiography: TEE is helpful, in particular, in cases with
moderate calcification. The additional value of three-
dimensional real-time TEE is currently being evaluated.
According to the limited current experience with intracardiac
echography, it does not seem to add to TEE in this setting.
† When positioning is considered correct, the prosthesis is
released. Rapid pacing is used at this stage in balloon expandable
but not in self-expanding devices.
† Immediately after TAVI, aortography and, whenever available,
TEE or, in the absence of TEE, eventually Transthoracic echo-
cardiogram (TTE) are performed to assess the location and
degree of aortic regurgitation and the patency of the coronary
arteries and to rule out complications such as haemopericar-
dium, and aortic dissection. The haemodynamic results are
assessed using pressure recordings and/or echocardiography.
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† After the procedure, the patients should stay in intensive care
for at least 24 h and be closely monitored for several days
especially as regards haemodynamics, vascular access, rhythm
disturbances (especially late atrioventricular block), and renal
function.
The following are the specific issues related to the different
approaches.
In the transfemoral approach, close attention should be paid to
the vascular access.
The common femoral artery can be either prepared surgically or
approached percutaneously. Echo-guided femoral access could be
useful. Manipulation of the introductory sheaths should be careful
and fluoroscopically guided. Depending on the size of the device,
closure of the vascular access can be effected surgically or using
a percutaneous closure device.11
For the transapical approach, femoral access and cardiopulmon-
ary bypass should be on standby in patients in whom surgical con-
version is an option in case of complications. The technique
requires an antero-lateral mini-thoracotomy, pericardiotomy,
identification of the apex, and then puncture of the left ventricle
using a needle through purse-string sutures. Subsequently, an
introductory sheath is positioned in the LV, and the prosthesis is
implanted using the anterograde route.
Results
Since the first-in-man TAVI by Alain Cribier in 2002, well over
1000 high-risk patients with severe symptomatic AS have been
treated using TAVI (as of January 2008).
Transfemoral approach
Over 400 cases have been performed using the balloon-
expandable and another 500 using the self-expandable prosthesis
(Company sources January 2008). Reports originate from a
limited number of centres worldwide.12– 17 The patients treated
were mostly .80 years old, at high risk (e.g. Logistic EuroScore.
20% in most cases), or with contraindications for surgery.
The overall results can be summarized as follows:
Procedural success is closely linked to experience and is 90%
in experienced centres. A learning curve can also be observed
resulting in better patient selection and outcomes. Valve function
is good with a final valve area ranging from 1.5 to 1.8 cm2.
Mortality at 30 days ranges from 5 to 18%. Acute myocardial
infarction occurs in 2–11%. Coronary obstruction is rare (,1%).
Mild-to-moderate aortic regurgitation, mostly paravalvular, is
observed in 50% of cases. However, the availability of larger
prostheses and their more careful matching with the size of the
aortic annulus led to the decrease in the incidence of severe
aortic regurgitation to 5%. Prosthesis embolization is rare, 1%.
Vascular complications, with an incidence ranging from 10 to
15%, remain a significant cause of mortality and morbidity.
Stroke ranges from 3 to 9%. Finally, atrioventricular block occurs
in 4–8%, necessitating pacemaker implantation in up to 24%
with self-expandable devices.
Long-term results up to 2 years (though only 1 year in most
studies) are reported in a limited number of patients. They show
a survival rate of 70–80% with a significant improvement in clinical
condition in most cases. The majority of late deaths are due to
comorbidities.
Serial echocardiographic studies have consistently shown good
prosthetic valve function with no structural deterioration of
valve tissue.
Transapical approach
The total experience with transapical aortic valve implantation
comprises over 300 patients, also at high risk for conventional
surgery, even more so because of concomitant peripheral arterial
disease in most cases. Experience currently reported only relates
to the balloon-expandable prosthesis,18–21 although, the first in
man has been recently performed with the self-expandable device.
The implantation success rate of the transapical procedure is
90%. Over 70% of cases are done off pump, the figure being
90% in experienced centres, and the rate of peri-operative conver-
sion is 9–12%. Mortality rates range from 9 to 18%. The incidence
of stroke is 0–6%. The quality of the results seems closely related
to experience as well as the availability of high-quality imaging in
the operating theatre.19
There are currently no direct comparative studies available for
the two approaches.
Perspectives
Progress in delivery systems and valve manufacturing could lead to
lower profile, repositionable, retrievable, and more durable
devices, as well as a wider range of prosthetic valve dimensions.
Furthermore, improved imaging, such as online three-dimensional
reconstruction and stereotaxis, could facilitate valve placement.
Pending questions
In the light of the current experience, bearing in mind the pre-
viously mentioned, inherent limitations of any conclusions, TAVI
using both balloon- and self-expandable devices can be said to
be feasible. Short- and mid-term haemodynamic results are good
up to 2 years. However, the technique remains challenging, in par-
ticular, as regards vascular access, device sizing, and positioning.
The major concerns as regards to safety are as follows:
† Vascular complications with the transfemoral approach, which
should decrease with smaller devices.
† Stroke rate, in particular, when using the transfemoral approach.
† Long-term consequences of paravalvular leaks, even if
mild-to-moderate regurgitation is considered not to have signifi-
cant clinical consequences in the short-term.
† Atrioventricular block, the incidence, timing, and predictors of
which have to be identified more precisely.
Mid (short)-term clinical outcome is encouraging, however,
long-term durability of these bioprostheses and the incidence of
endocarditis or thrombo-embolic events remain key questions,
especially if considering lowering the threshold for indication.
The feasibility of subsequent aortic valve intervention is not
known.
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Recommendations for the
development of transcatheter
aortic valve implantation
Patient selection
Selection of candidates for TAVI, especially risk assessment, should
involve multi-disciplinary consultation between cardiologists, sur-
geons, imaging specialists, anaesthesiologists, and possibly other
specialists if necessary.
TAVI is indicated in patients with calcified pure or predominant
AS. It is unlikely that it will be used in patients with pure aortic
regurgitation.
Degeneration of an implanted aortic bioprosthesis (valve-in-
valve implantation) is an attractive potential indication because of
the high risk of re-operation in elderly patients. However, the
current experience is too limited to make any recommendations.
The following are the four steps of patient selection:
† confirmation the severity of AS;
† evaluation of symptoms;
† analysis of the risk of surgery and evaluation of life expectancy
and quality of life;
† assessment of the feasibility and exclusion of contraindications
for TAVI.
Confirmation of the severity of aortic stenosis
TAVI should be performed only in severe AS. Echocardiography is
the preferred tool to assess the severity of AS according to a com-
bination of measurements of valve area and flow-dependent
indices. Low-dose dobutamine echocardiography is useful to differ-
entiate between severe and the rare ‘pseudo severe’ AS in patients
with low LV ejection fraction and low gradient.3,4
Evaluation of symptoms
At the present stage, TAVI should only be proposed in patients
with severe symptoms that can definitely be attributed to valve
disease because of pending questions on safety and valve durability.
Analysis of the risks of surgery, and evaluation of life
expectancy and quality of life
Decision-making is particularly complex in these elderly patients
who represent a heterogeneous population and require balanced
and individualized analysis.
The evaluation of the risk of surgery is based on the assessment
of cardiac and extra cardiac factors.22 Risk scores, such as the Euro-
Score,23 the STS Predicted Risk of Mortality score,24 or the Ambler
score,25 are of interest. However, they all share similar limitations:
predictive ability is reduced in these high-risk patients who rep-
resent only a small proportion of the population from which the
scores were elaborated; and high-risk patients form a particularly
heterogeneous group in which it is difficult to capture all the comor-
bidities. The value of individual scores in this high-risk population has
yet to be specifically established.26 The predictive value of these
scores for morbidity and long-term results is also unknown.
TAVI should currently be restricted to patients at high-risk or
with contraindications for surgery. It is premature to consider
using it in patients who are good surgical candidates.
For the Committee, the key element to establish whether
patients are at high risk for surgery is clinical judgement, which
should be used in association with a more quantitative assessment,
based on the combination of several scores (for example expected
mortality .20% with the Logistic EuroScore and .10% with STS
score). This approach allows the team to take into account risk
factors that are not covered in scores but often seen in practice
such as chest radiation, previous aorto-coronary bypass with
patent grafts, porcelain aorta, liver cirrhosis, etc. Surgical risk esti-
mation should also bear in mind results in the given institution.27
At this stage, TAVI is not recommended for patients who simply
refuse surgery on the basis of personal preference.
Life expectancy is most significantly influenced by comorbidities,
which should be carefully looked for. In addition to clinical
evaluation, semi-quantitative scoring systems, such as those used
in geriatrics, may be helpful.28 Today, TAVI is seldom considered
in patients ,70, however, age alone is not sufficient for its use
instead of surgery. TAVI should not be performed in patients
whose life expectancy is ,1 year, who should be managed
conservatively.
Assessment of feasibility and exclusion of
contraindications of transcatheter aortic valve
implantation
The following steps should be taken to assess the feasibility of
TAVI:
Assessment of the coronary anatomy
Coronary angiography should be performed to this end. If associ-
ated coronary artery disease requires revascularization, whether to
proceed surgically, percutaneously, or in a hybrid manner, as well
as the chronology of interventions, should be the subject of indivi-
dualized discussion based on the patient’s clinical condition and
anatomy. TAVI is probably not recommended in patients with
severe proximal coronary stenoses not amenable to percutaneous
coronary interventions.
The position of the coronary arteries relative to the aortic cusps
can be assessed using aortography or multislice computed
tomography.29
Measurement of the aortic annulus
Correct sizing of the valve is critical to minimize the potential for
paravalvular leakage and to avoid prosthesis migration after place-
ment; however, a gold standard method of measurement has yet to
be established. TEE has been found to show larger values than
transthoracic echocardiography, thus, it should be performed if
borderline values lead to doubt the feasibility of the procedure.30
Multislice computed tomography29 or magnetic resonance imaging
could also be used for this purpose. Finally, aortography measure-
ments performed during BAV are also useful.
Echocardiography is the preferred tool for the assessment of the
morphology of the LV outflow tract and, before implanting self-
expandable devices, the dimensions of the aortic root.
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Evaluation of size, tortuosity, and calcification of peripheral arteries
Angiography is the reference; however, multislice computed tom-
ography can also be used. Finally, magnetic resonance imaging is
helpful in patients with renal insufficiency.
Some contraindications are general, whereas others are
approach- or device-specific.
General contraindications for TAVI are as follows:
† Aortic annulus, 18 or .25 mm for balloon-expandable and
,20 or .27 for self-expandable devices
† Bicuspid valves because of the risk of incomplete deployment of
the prosthesis31
† Presence of asymmetric heavy valvular calcification, which may
compress the coronary arteries during TAVI.15 The bulk and dis-
tribution of calcification in the valve may be assessed by fluoro-
scopy and multislice computed tomography. Finally, the risk of
coronary compression can be anticipated during BAV.
† Aortic root dimension . 45 mm at the aorto-tubular junction
for self-expandable prostheses.
† Presence of apical LV thrombus.
The specific indications for transfemoral and transapical
approaches are not fully established and should be discussed
according to patient condition and local expertise.
Contraindications of the transfemoral approach are as follows:
† Iliac arteries: severe calcification, tortuosity, small diameter (,6
to 9 mm according to the device used), previous aorto-femoral
bypass.
† Aorta: severe angulation, severe atheroma of the arch, coarcta-
tion, aneurysm of the abdominal aorta with protruding mural
thrombus.
† Presence of bulky atherosclerosis of the ascending aorta and
arch detected by TEE
† Transverse ascending aorta (balloon-expandable device).
Contraindications for the transapical approach are as follows:
† previous surgery of the LV using a patch, such as the Dor
procedure;
† calcified pericardium;
† severe respiratory insufficiency;
† non-reachable LV apex.
Performance of transcatheter aortic valve
implantation
The performance of TAVI, even more so ab initio, should be
restricted to a limited number of high-volume centres, which
have both cardiology and cardiac surgery departments, with exper-
tise in structural heart disease intervention and high-risk valvular
surgery.
The procedure requires the close cooperation of a team of
specialists in valve disease, including clinical cardiologists, echocar-
diographists, interventional cardiologists, cardiac surgeons, and
anaesthesiologists.
Interventional cardiologists should be experienced in catheter-
based valvular interventions, and peripheral access using large
devices.
Cardiac surgeons should be experienced in valve surgery and
the management of complex cases.
The final organization may vary from centre to centre and
according to the type of procedure.
A multidisciplinary team approach and cross-fertilization will be
fundamental in the development of these procedures.
Because of the severe clinical condition of these patients, the
presence of anaesthesiologists with specific expertise in cardiology
is mandatory for peri- and post-operative care in collaboration
with cardiologists and cardiovascular surgeons.
A close collaboration with surgeons skilled in vascular access
repair and endo-vascular procedures is recommended for transfe-
moral aortic valve implantation.
The aim of TAVI training is to acquire basic, then advanced, and
finally device-specific skills. It will concentrate on knowledge of
valve disease (clinical assessment, catheterization techniques,
imaging), working in a sterile environment, access management,
understanding the equipment, and anticipation and treatment of
complications. Training will be through didactic sessions, bench
and/or computer simulators, animal laboratories, hands-on train-
ing, participation in established workshops, and proctoring during
the first cases.
The field of teaching and certification needs to be significantly
developed. A new subspecialization may be necessary with a
common training pathway for cardiologists and surgeons wishing
to practice TAVI.
At this early stage, data are insufficient to define a minimum
number of procedures required for competency. Furthermore,
individual experience must be continued in order to conserve
skills.
As regards the logistics, it is agreed that the operating room and
the catheterization laboratory should be as close as possible to
guarantee optimum patient safety. The optimal environment for
TAVI should be spacious and sterile, and feature high-quality
imaging equipment, and haemodynamic monitoring and recording
capabilities. However, where to find such an environment is still
under debate, as both current surgical and interventional suites
are suboptimal. Catheterization laboratories have good quality
imaging but may not be sterile and may induce delay in rescue
surgery. The opposite is often the case for operating rooms.
A hybrid suite is ideal as it fulfils the role of both an operating
room and a catheterization laboratory. However, most institutions
do not have a hybrid room available, thus, the organizational and
financial implications of acquiring one, which is highly desirable,
cannot be overlooked.
It is the role of professional organizations such as the EACTS
and the ESC and their national equivalents to set the standards
for performance of the procedure and training and accreditation
on an individual and institutional level.
Evaluation of the results
Evaluation of the results of TAVI will present a significant challenge
because of the unique characteristics of this patient population.
Thus, comparison with current outcome standards may not be
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appropriate. Close collaboration between investigators, regulators,
and the industry should be assured early on.
The evaluation of new devices or techniques should be per-
formed in accordance with the stipulations of the regulating auth-
orities.32,33 In Europe, TAVI devices are classified in the highest risk
group (class 3) as regards the requirements for the putting of new
devices on the market.32 Evaluation should adhere to the following
pattern: bench testing, in vitro, and animal implantation studies
(including bio-compatibility studies), then, only when sufficient
data are available, clinical investigation.
Clinical investigation should begin with the proof of concept
feasibility studies, followed by prospective clinical investigations
to determine safety and performance.34
Randomized trials are the most rigorous design to evaluate
safety and efficacy in relation to other treatment modalities.
However, this is difficult with TAVI in relation to the most high-risk
patients, many of whom are currently not operated on mostly due
to non-referral.7 Furthermore, the contemporary natural history of
unoperated patients is incompletely known.
The Committee believes that randomized trials are highly desir-
able once greater experience has been acquired, and only small
modifications in the technology used are to be expected. The
necessary clear definition of entry criteria for these trials may be
hindered by the inadequacy of risk scores in these high-risk
patients (see the section ‘Analysing the risks of surgery’ for more
details).
In high-risk operable patients, TAVI should be compared with
valve replacement, in particular with the perspective of patients
who are in better clinical condition in the future. In these patients,
efficacy could be tested as non-inferiority vs. surgery, avoiding a
too large delta, whereas safety can be tested as superiority to
surgery. In non-operable patients, TAVI can be compared with
the best available medical treatment using the superiority design
for efficacy; however, this is more debatable and probably more
difficult to run. A randomized trial, PARTNER US, is currently
ongoing where the primary endpoint is all-cause mortality at 1
year. In the future, the extension of TAVI to a lower risk patient
population should occur only in the setting of a randomized trial.
As well as enrolment in randomized controlled trials, data
should be accumulated in registries. Such registries, which may
be regional, national, or international, are mandatory in the evalu-
ation of TAVI before its release in the general medical community.
Completeness of the data is essential here. The duration of
follow-up to assess safety should be at least 1 year in the pre-
market phase and ideally 5 years for post-marketing surveillance.
Retrieval studies should also be carried out if appropriate.
Irrespective of the study design, safety and efficacy endpoints
must be carefully defined.
Analysis will include the standard major adverse cardiac events:
mortality (30 day, in hospital, 1 year), stroke, myocardial infarction,
re-hospitalization, reoperation, arrhythmias, and conduction dis-
turbances. All adverse events, anticipated and non-anticipated,
should also be reported to the health authority. Quality of life is
paramount, in particular, in these populations; thus, improvement
should be recorded using quality of life metrics, which should be
combined with cost effectiveness parameters. Endpoints assessing
valve function should follow the guidelines developed for valve
surgery and include structural and non-structural valve dysfunction,
endocarditis, thrombo-embolism and bleeding events.
Secondary endpoints, particular to TAVI, should also include
valve area and transvalvular gradient measurement, paravalvular
leaks, device migration, emergency valve-in-valve implantation,
conversion to conventional surgery, and vascular complications.
These trials should be performed according to the standards for
clinical trials, i.e. central data collection and analysis, data and safety
monitoring board, core laboratory analysis, and auditing and quality
control, all respecting the rules of independence from sponsors.
TAVI should currently be performed only in clinical studies or as
part of post-marketing registries. Clinical trials should be limited to
centres with experience in TAVI and trials, and which actively par-
ticipate in internal evaluation.
In centres performing TAVI, multi-disciplinary meetings should
be held on a regular basis to discuss indications, procedural tech-
niques, and case outcomes. Hospitals should keep proof of close
medico-surgical collaboration and maintain a log of all patients
referred for TAVI, regardless of final treatment strategy, for con-
tinuous evaluation of the programme.35 Furthermore, a series of
thorough quality assurance measures should be included.
Conclusion
The currently available results obtained with TAVI suggest that
these techniques are feasible and provide haemodynamic and clini-
cal improvement for up to 2 years in patients with severe sympto-
matic AS at high risk or with contraindications for surgery. Pending
questions concern mainly safety and long-term durability. Surgeons
and cardiologists must work as a team to select the best candi-
dates, perform the procedure, and, finally, evaluate the results.
Today, these techniques are targeted at high-risk patients but
they may be extended to the lower risk group in the future, if
the initial promise holds true after careful evaluation. We are cur-
rently at the stage of evaluation, and a careful commercialization
process including training and post-market surveillance is crucial
to avoid the risk of uncontrolled diffusion, which is wholly undesir-
able at this stage of evolution of these techniques.
Conflict of interest: The following authors declared the follow-
ing conflicts of interest: J.B., research grants from GE Healthcare,
BMS Medical Imaging, St Jude, Medtronic, Boston Scientific; A.C.,
consultant for Edwards Lifesciences; J.K., consultant for Medtronic;
F.M., consultant for Edwards Lifesciences and Medtronic, consult-
ant and stockholder for Micardia; P.N., consultant for Sorin; J.L.P.,
consultant for Edwards Lifesciences and Boston Scientific; A.V.,
consultant for Edwards Lifesciences; B.v.H., scientific director on
a cost effectiveness study concerning PVR sponsored by Edwards
Lifesciences; L.K.v.S., founder and shareholder of Smartcanula
LLC, Lausanne, Switzerland. All other authors have no conflicts
of interest to declare.
Funding
Edwards Lifesciences provided an unrestricted grant for the practical
organization of the meeting. No representatives of Edwards Life-
sciences attended the meeting or were involved in the elaboration
of the document.
A. Vahanian et al1468
References
1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,
Enriquez-Sarano M. Burden of valvular heart diseases: a
population-based study. Lancet 2006;368:1005–1011.
2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Ba¨rwolf C,
Levang OW, Tornos P, Vanoverschelde JL, Vermeer F,
Boersma E, Ravaud P, Vahanian A. A prospective survey of patients
with valvular heart disease in Europe: The Euro Heart Survey on
valvular disease. Eur Heart J 2003;24:1231–1243.
3. American College of Cardiology/American Heart Association Task
Force on Practice Guidelines, Society of Cardiovascular Anesthe-
siologists, Society for Cardiovascular Angiography Interventions,
Society of Thoracic Surgeons; Bonow RO, Carabello BA,
Kanu C, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH,
Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM,
Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD,
Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL,
Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B.
ACC/AHA 2006 guidelines for the management of patients with
valvular heart disease: a report of the American College of Cardi-
ology/American Heart Association Task Force on Practice Guide-
lines (Writing Committee to revise the 1998 Guidelines for the
Management of Patients with Valvular Heart Disease): developed
in collaboration with the Society of Cardiovascular Anesthesiolo-
gists: endorsed by the Society for Cardiovascular Angiography and
Interventions and the Society of Thoracic Surgeons. Circulation
2006;114:e84–e231.
4. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R,
Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P,
Tornos P, Torracca L, Wenink A. Task Force on the Management
of Valvular Heart Disease of the European Society of Cardiology;
ESC Committee for Practice Guidelines. Guidelines on the man-
agement of valvular heart disease: The Task Force on the Manage-
ment of Valvular Heart Disease of the European Society of
Cardiology. Eur Heart J 2007;28:230–268.
5. Kolh P, Kerzmann A, Honore C, Comte L, Limet R. Aortic valve
surgery in octogenarians: predictive factors for operative and
long term results. Eur J Cardiothorac Surg 2007;31:600–606.
6. Melby SJ, Zierer A, Kaiser YP, Guthrie TJ, Keune JD, Schuessler RB,
Pasque MK, Lawton JS, Moazami N, Moon MJ, Damiano RJ Jr.
Aortic valve replacement in octogenarians. Risk factors for early
and late mortality. Ann Thorac Surg 2007;83:1651–1657.
7. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F,
Tornos P, Gohlke-Ba¨rwolf C, Boersma E, Ravaud P, Vahanian A.
Decision-making in elderly patients with severe aortic stenosis:
why are so many denied surgery? Eur Heart J 2005;26:2714–2720.
8. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F,
Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous
transcatheter implantation of an aortic valve prosthesis for calcific
aortic stenosis: first human case description. Circulation 2002;106:
3006–3008.
9. Vassiliades TA Jr, Block PC, Cohn LH, Adams DH, Borer JS,
Feldman T, Holmes DR, Laskey WK, Lytle BW, Mack MJ,
Williams DO; Society of Thoracic Surgeons (STS), American
Association for Thoracic Surgery (AATS), Society for Cardiovas-
cular Angiography Interventions (SCAI), American College of Car-
diology Foundation (ACCF), American Heart Association (AHA).
The clinical development of percutaneous heart valve technology:
a position statement of the Society of Thoracic Surgeons (STS),
the American Association for Thoracic Surgery (AATS), and the
Society for Cardiovascular Angiography and Interventions
(SCAI). Ann Thorac Surg 2005;79:1812–1818.
10. Rosengart TK, Feldman T, Borger MA, Vassiliades TA Jr,
Gillinov AM, Hoercher KJ, Vahanian A, Bonow RO, O’Neill W.
Percutaneous and minimally invasive valve procedures. A scientific
statement from the American Heart Association Council on
Cardiovascular Surgery and Anesthesia, Council on Clinical
Cardiology, Functional Genomics and Translational Biology Inter-
disciplinary Working Group, and Quality of Care and Outcomes
Research Interdisciplinary Working Group. Circulation 2008;117:
1750–1767.
11. De Jaegere P, Van Dijk LC, Laborde JC, Sianos G,
Orellana Ramos FJ, Lighart J, Kappetein AP, van der Ent M,
Serruys PW. True percutaneous implantation of the CoreValve
aortic valve prosthesis by the combined use of ultrasound
guided vascular access, Prostarw XL and the TandemHeartw.
EuroIntervention 2007;2:500–505.
12. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L,
Bash A, Nusimovici D, Litzler PY, Bessou JP, Leon MB. Early
experience with percutaneous transcatheter implantation of
heart valve prosthesis for the treatment of end-stage inoperable
patients with calcific aortic stenosis. J Am Coll Cardiol 2004;43:
698–703.
13. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C,
Nercolini D, Tapiero S, Litzler PY, Bessou JP, Babaliaros V. Treat-
ment of calcific aortic stenosis with the percutaneous heart valve:
mid-term follow-up from the initial feasibility studies: the French
experience. J Am Coll Cardiol 2006;47:1214–1223.
14. Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B,
Buellesfeld L, Mueller R, Menichelli M, Schmidt T, Zickmann B,
Iversen S, Stone GW. Percutaneous implantation of the CoreValve
self-expanding valve prosthesis in high-risk patients with aortic
valve disease: the Siegburg first-in-man study. Circulation 2006;
114:1616–1624.
15. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG,
Munt BI, Buller CE, Pasupati S, Lichtenstein S. Percutaneous
aortic valve implantation retrograde from the femoral artery. Circu-
lation 2006;113:842–850.
16. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L,
Moss R, Sinhal A, Carere RG, Munt B, Ricci D, Ye J, Cheung A,
Lichtenstein SV. Percutaneous transarterial aortic valve replace-
ment in selected high-risk patients with aortic stenosis. Circulation
2007;116:755–763.
17. Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A,
Wenaweser P, Sauren B, Mohr FW, Walther T, Zickmann B,
Iversen S, Felderhoff T, Cartier R, Bonan R. Percutaneous aortic
valve replacement for severe aortic stenosis in high-risk patients
using the second- and current third-generation self-expanding
CoreValve prosthesis: device success and 30-day clinical
outcome. J Am Coll Cardiol 2007;50:69–76.
18. Lichtenstein SV, Cheung A, Ye J, Thompson CR, Carere RG,
Pasupati S, Webb JG. Transapical transcatheter aortic valve implan-
tation in humans: initial clinical experience. Circulation 2006;114:
591–596.
19. Walther T, Falk V, Borger MA, Dewey T, Wimmer-Greinecker G,
Schuler G, Mack M, Mohr FW. Minimally invasive transventricular
beating heart aortic valve implantation—proof of concept. Eur J
Cardiothorac Surg 2007;31:9–15.
20. Walther T, Simon P, Dewey T, Wimmer-Greinecker G, Falk V,
Kasimir MT, Doss M, Borger MA, Schuler G, Glogar D,
Fehske W, Wolner E, Mohr FW, Mack M. Transapical minimally
Transcatheter valve implantation 1469
invasive aortic valve implantation: multicenter experience. Circula-
tion 2007;116(suppl.):I240–I245.
21. Ye J, Cheung A, Lichtenstein SV, Pasupati S, Carere RG,
Thompson CR, Sinhal A, Webb JG. Six-month outcome of transa-
pical transcatheter aortic valve implantation in the initial seven
patients. Eur J Cardiothorac Surg 2007;31:16–21.
22. Edwards FH, Peterson ED, Coombs LP, DeLong ER, Jamieson WR,
Shroyer ALW, Grover FL. Prediction of operative mortality
after valve replacement surgery. J Am Coll Cardiol 2001;37:
885–892.
23. Roques F, Nashef SA, Michel P; EuroSCORE study group. Risk
factors for early mortality after valve surgery in Europe in the
1990s: lessons from the EuroSCORE pilot program. J Heart Valve
Dis 2001;10:572–577.
24. STS National Database. STS US Cardiac Surgery Database: 1997
Aortic Valve Replacement Patients: Preoperative Risk Variables.
Chicago: Society of Thoracic Surgeons; 2000. http://www.ctsnet.
org/doc/3031 (10 May 2006).
25. Ambler G, Omar RZ, Royston P, Kinsman R, Keogh BE, Taylor KM.
Generic, simple risk stratification model for heart valve surgery.
Circulation 2005;112:224–231.
26. Dewey TM, Brown D, Ryan WH, Herbert MA, Prince SL, Mack MJ.
Reliability of risk algorithms in predicting early and late operative
outcomes in high-risk patients undergoing aortic valve replace-
ment. J Thorac Cardiovasc Surg 2008;135:180–187.
27. Schelbert EB, Vaughan-Sarrazin MS, Welke KF, Rosenthal GE.
Hospital volume and selection of valve type in older patients
undergoing aortic valve replacement surgery in the United
States. Circulation 2005;111:2178–2182.
28. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and vali-
dation of a prognostic index for 4-year mortality in older adults.
JAMA 2006;295:801–808. Erratum in JAMA;2006:295:1900.
29. Tops LF, Wood DA, Delgado V, Schuijf JD, Mayo JR, Pasupati S,
Lamers FPL, van der Wall EE, Schalij MJ, Webb JG, Bax JJ. Nonin-
vasive evaluation of the aortic root with multislice computed tom-
ography: implications for transcatheter aortic valve replacement.
J Am Coll Cardiol Imaging 2008; in press.
30. Moss RR, Ivens E, Pasupati S, Humphries K, Thompson CR,
Munt B, Sinhal A, Webb JG. Role of echocardiography in percuta-
neous aortic valve implantation. J Am Coll Cardiol Imaging 2008;1:
15–24.
31. Zegdi R, Ciobotaru V, Noghin M, Sleilaty G, Lafont A,
Latre´mouille C, Deloche A, Fabiani JN. Is it reasonable to treat
all calcified stenotic aortic valves with a valved stent? Results
form a human anatomic study in adults. J Am Coll Cardiol 2008;
51:579–584.
32. Ludgate S. A user’s guide to overcoming roadblocks: the European
approval process. EuroIntervention 2006;1(Suppl. A):A79–A80.
33. Zuckerman BD. The FDA role in the development of percuta-
neous heart valve technology. EuroIntervention 2006;1(Suppl. A):
A75–A78.
34. Grunkemeier GL, Jin R, Starr A. Prosthetic heart valves: objective
performance criteria versus randomised clinical trial. Ann Thorac
Surg 2006;82:776–780.
35. Descoutures F, Himbert D, Lepage L, Iung B, De´taint D,
Tchetche D, Brochet E, Castier Y, Depoix JP, Nataf P,
Vahanian A. Contemporary surgical or percutaneous management
of severe aortic stenosis in the elderly. Eur Heart J 2008; epub
ahead of print 6 March.
A. Vahanian et al1470
